{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-003513","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.667680+00:00","generated_at":"2026-05-21T08:38:18.171883+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenetic Biosciences Q1 2025: net loss $0.9M, revenue $0.6M (+16%), cash $5.2M","bullets":["Net loss of ~$0.9M for Q1 2025; revenue increased 16.1% to ~$0.6M from $0.5M in Q1 2024.","Total operating costs decreased 13.7% to ~$1.5M, primarily due to lower personnel costs after CEO/CSO departures in mid-2024.","Cash position of $5.2M at quarter end; no guidance or dividend changes.","Advancing DNase I platform; collaboration with PeriNess for exploratory studies in osteosarcoma, Ewing sarcoma, and pancreatic carcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-003513","json":"https://secwatch.observer/filing/0001683168-25-003513.json","markdown":"https://secwatch.observer/filing/0001683168-25-003513.md","text":"https://secwatch.observer/filing/0001683168-25-003513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316825003513/0001683168-25-003513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316825003513/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:38:18.171883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}